Medscape is available in 5 Language Editions – Choose your Edition here.


Diarrhea Treatment & Management

  • Author: Stefano Guandalini, MD; Chief Editor: Carmen Cuffari, MD  more...
Updated: Aug 19, 2015

Medical Care

In 2003 the Center for Disease Control (CDC) put forth recommendations for the management of acute pediatric diarrhea in both the outpatient and inpatient settings including indication for referral.[2]

Indications for medical evaluation of children with acute diarrhea include the following:

  • Younger than 3 months
  • Weight of less than 8 kg
  • History of premature birth, chronic medical conditions, or concurrent illness
  • Fever of 38ºC or higher in infants younger than 3 months or 39ºC or higher in children aged 3-36 months
  • Visible blood in the stool
  • High-output diarrhea
  • Persistent emesis
  • Signs of dehydration as reported by caregiver, including sunken eyes, decreased tears, dry mucous membranes, and decreased urine output
  • Mental status changes
  • Inadequate responses to oral rehydration therapy (ORT) or caregiver unable to administer ORT

The report also includes information on assessment of dehydration and what steps should be taken to adequately treat acute diarrhea.

Treatment of dehydration due to diarrhea includes the following:

  • Minimal or no dehydration
    • Rehydration therapy - Not applicable
    • Replacement of losses
      • Less than 10 kg body weight - 60-120 mL oral rehydration solution for each diarrhea stool or vomiting episode
      • More than 10 kg body weight - 120-140 mL oral rehydration solution for each diarrhea stool or vomiting episode
  • Mild-to-moderate dehydration
    • Rehydration therapy - Oral rehydration solution (50-100 mL/kg over 3-4 h)
    • Replacement of losses
      • Less than 10 kg body weight - 60-120 mL oral rehydration solution for each diarrhea stool or vomiting episode
      • More than 10 kg body weight - 120-140 mL oral rehydration solution for each diarrhea stool or vomiting episode
  • Severe dehydration
    • Rehydration therapy - Intravenous lactated Ringer solution or normal saline (20 mL/kg until perfusion and mental status improve), followed by 100 mL/kg oral rehydration solution over 4 hours or 5% dextrose (half normal saline) intravenously at twice maintenance fluid rates
    • Replacement of losses
      • Less than 10 kg body weight - 60-120 mL oral rehydration solution for each diarrhea stool or vomiting episode
      • More than 10 kg body weight - 120-140 mL oral rehydration solution for each diarrhea stool or vomiting episode
      • If unable to drink, administer through nasogastric tube or intravenously administer 5% dextrose (one fourth normal saline) with 20 mEq/L potassium chloride

ORT is the cornerstone of treatment, especially for small-bowel infections that produce a large volume of watery stool output. ORT with a glucose-based oral rehydration syndrome must be viewed as by far the safest, most physiologic, and most effec­tive way to provide rehydration and maintain hydration in children with acute diarrhea worldwide, as recommended by the WHO; by the ad hoc committee of European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN); and by the American Academy of Pediatrics.[9] However, the global use of ORT is still insufficient. Developed countries, in particular the United States, seem to be lagging behind despite studies that demonstrate beyond doubt the efficacy of ORT in emergency care settings, in which intravenous rehydration unduly continues to be widely privileged.

Not all commercial ORT formulas promote optimal absorption of electrolytes, water, and nutrients. The ideal solution has a low osmolarity (210-250) and a sodium content of 50-60 mmol/L. Administer maintenance fluids plus replacement of losses. Educate caregivers in methods necessary to replace this amount of fluid. Administer small amounts of fluid at frequent intervals to minimize discomfort and vomiting. A 5-mL or 10-mL syringe without a needle is a very useful tool. The syringe can be quickly used to place small amounts of fluid in the mouth of a child who is uncooperative. Once the child becomes better hydrated, cooperation improves enough to take small sips from a cup. This method is time intensive and requires a dedicated caregiver. Encouragement from the physician is necessary to promote compliance. Oral rehydration is now universally recommended to be completed within 4 hours.

The addition of zinc to oral rehydration solution has been proven effective in children with acute diarrhea in developing countries and is recommended by the WHO.[10] However, no evidence suggests efficacy in children living in developed countries, in which the prevalence of zinc deficiency is assumed to be extremely low.

The composition of almost all other beverages (carbonated or not) that are commercially available and frequently used in children with diarrhea is completely inadequate for rehydration or for maintaining hydration, considering the sodium content, which is invariably extremely low, and osmolarity that is often dangerously elevated. For instance, Coca-Cola, Pepsi-Cola, and apple juice have an osmolarity of 493, 576, and 694-773, respectively.

At completion of hydration, resumption of feeding is strongly recommended. In fact, many studies convincingly demonstrate that early refeeding hastens recovery. Also, robust evidence suggests that, in the vast majority of episodes of acute diarrhea, refeeding can be accomplished without the use of any special (eg, lactose-free or soy-based) formulas.

Antimotility agents are not indicated for infectious diarrhea, except for refractory cases of Cryptosporidium infection. Antimicrobial therapy is indicated for some nonviral diarrhea because most is self-limiting and does not require therapy.

Therapies recommended for some nonviral diarrheas include the following:

  • Aeromonas species: Use cefixime and most third-generation and fourth-generation cephalosporins.
  • Campylobacter species: Erythromycin shortens illness duration and shedding.
  • C difficile: Discontinue potential causative antibiotics. If antibiotics cannot be stopped or this does not result in resolution, use oral metronidazole or vancomycin. Vancomycin is reserved for the child who is seriously ill.
  • C perfringens: Do not treat with antibiotics.
  • Cryptosporidium parvum: Administer paromomycin; however, effectiveness is not proven. Nitazoxanide, a newer anthelmintic, is effective against C parvum.
  • Entamoeba histolytica: Metronidazole followed by iodoquinol or paromomycin is administered in symptomatic patients. Asymptomatic carriers in nonendemic areas should receive iodoquinol or paromomycin.
  • E coli: Trimethoprim-sulfamethoxazole (TMP-SMX) should be administered if moderate or severe diarrhea is noted; antibiotic treatment may increase likelihood of hemolytic-uremic syndrome (HUS). Parenteral second-generation or third-generation cephalosporin is indicated for systemic complications.
  • G lamblia: Metronidazole or nitazoxanide can be used.
  • Plesiomonas species: Use TMP-SMX or any cephalosporin.
  • Salmonella species: Treatment prolongs carrier state, is associated with relapse, and is not indicated for nontyphoid-uncomplicated diarrhea. Treat infants younger than 3 months and high-risk patients (eg, immunocompromised, sickle cell disease). TMP-SMX is first-line medication; however, resistance occurs. Use ceftriaxone and cefotaxime for invasive disease.
  • Shigella species: Treatment shortens illness duration and shedding but does not prevent complications. TMP-SMX is first-line medication; however, resistance occurs. Cefixime, ceftriaxone, and cefotaxime are recommended for invasive disease.
  • V cholerae: Treat infected individuals and contacts. Doxycycline is the first-line antibiotic, and erythromycin is second-line antibiotic.
  • Yersinia species: TMP-SMX, cefixime, ceftriaxone, and cefotaxime are used. Treatment does not shorten disease duration; reserve for complicated cases.


See the list below:

  • Surgeon
    • Certain organisms cause abdominal pain and bloody stools.
    • Symptoms resembling appendicitis, hemorrhagic colitis, intussusception, or toxic megacolon may be appreciated.
    • If the infectious etiology in individuals with such symptoms is not certain, seek consultation with a surgeon.
  • Infectious-disease specialist: Consider consultation with an infectious-disease specialist for any patient who is immunocompromised because of HIV infection, chemotherapy, or immunosuppressive drugs because atypical organisms are more likely, and complications can be more serious and fulminate.


Breastfed infants with acute diarrhea should be continued on breast milk without any need for interruption. In fact, breastfeeding not only has a well-known protective effect against the development of enteritis, it also promotes faster recovery and provides improved nutrition. This is even more important in developing countries, where with­drawal of breastfeeding during diarrhea has been shown to have a deleterious effect on the development of dehydra­tion in infants with acute watery diarrhea.

  • Bananas, rice, applesauce, and toast diet
    • A banana, rice, applesauce, and toast (BRAT) diet was introduced in the United States in 1926 and has enjoyed vast popularity. However, no evidence shows that this diet is useful, and its poor protein content may be a contraindication; therefore, it is not recommended.
    • A strong body of evidence now suggests that resuming the prediarrhea diet is perfectly safe and must be encouraged, obviously respecting any (usually temporary) lack of appetite.
  • Lactose ingestion
    • Although rotavirus can cause secondary transient lactose intolerance, this finding is believed to be generally not clinically relevant; use lactose-containing formulas in all individuals with diarrhea.
    • In an incident of worsening of diarrhea proven to be secondary to a clinically important lactose malabsorption in infants positive for rotavirus, a very transient use of lactose-free formulas (5-6 d) can be considered.
Contributor Information and Disclosures

Stefano Guandalini, MD Founder and Medical Director, Celiac Disease Center, Chief, Section of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, University of Chicago Medical Center; Professor, Department of Pediatrics, Section of Gastroenterology, Hepatology and Nutrition, University of Chicago Division of the Biological Sciences, The Pritzker School of Medicine

Stefano Guandalini, MD is a member of the following medical societies: American Gastroenterological Association, North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, European Society for Paediatric Gastroenterology, Hepatology & Nutrition, North American Society for the Study of Celiac Disease

Disclosure: Received consulting fee from AbbVie for consulting.


Richard E Frye, MD, PhD Associate Professor, Department of Pediatrics, University of Arkansas for Medical Sciences

Richard E Frye, MD, PhD is a member of the following medical societies: American Academy of Neurology, Child Neurology Society, International Neuropsychological Society, American Academy of Pediatrics

Disclosure: Nothing to disclose.

M Akram Tamer, MD Professor, Program Director, Department of Pediatrics, University of Miami, Leonard M Miller School of Medicine

M Akram Tamer, MD is a member of the following medical societies: American Medical Association, Florida Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Chief Editor

Carmen Cuffari, MD Associate Professor, Department of Pediatrics, Division of Gastroenterology/Nutrition, Johns Hopkins University School of Medicine

Carmen Cuffari, MD is a member of the following medical societies: American College of Gastroenterology, American Gastroenterological Association, North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, Royal College of Physicians and Surgeons of Canada

Disclosure: Received honoraria from Prometheus Laboratories for speaking and teaching; Received honoraria from Abbott Nutritionals for speaking and teaching.

Additional Contributors

Chris A Liacouras, MD Director of Pediatric Endoscopy, Division of Gastroenterology and Nutrition, Children's Hospital of Philadelphia; Associate Professor of Pediatrics, University of Pennsylvania School of Medicine

Chris A Liacouras, MD is a member of the following medical societies: American Gastroenterological Association

Disclosure: Nothing to disclose.

  1. Kling J. Green Tea and Pomegranate Extract Help Fight Diarrhea in Children. Medscape Medical News. Available at Accessed: October 24, 2014.

  2. King CK, Glass R, Bresee JS, Duggan C. Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy. MMWR Recomm Rep. 2003 Nov 21. 52:1-16. [Medline].

  3. Fischer TK, Viboud C, Parashar U, Malek M, Steiner C, Glass R, et al. Hospitalizations and deaths from diarrhea and rotavirus among children 111111111J Infect Dis</i>. 2007 Apr 15. 195(8):1117-25. [Medline].

  4. Cortese MM, Tate JE, Simonsen L, Edelman L, Parashar UD. Reduction in gastroenteritis in United States children and correlation with early rotavirus vaccine uptake from national medical claims databases. Pediatr Infect Dis J. 2010 Jun. 29(6):489-94. [Medline].

  5. Talbert A, Thuo N, Karisa J, Chesaro C, Ohuma E, Ignas J, et al. Diarrhoea complicating severe acute malnutrition in kenyan children: a prospective descriptive study of risk factors and outcome. PLoS One. 2012. 7(6):e38321. [Medline]. [Full Text].

  6. Esposito DH, Holman RC, Haberling DL, Tate JE, Podewils LJ, Glass RI, et al. Baseline estimates of diarrhea-associated mortality among United States children before rotavirus vaccine introduction. Pediatr Infect Dis J. 2011 Nov. 30(11):942-7. [Medline].

  7. Mehal JM, Esposito DH, Holman RC, Tate JE, Sinden LL, Parashar UD. Risk Factors for Diarrhea-Associated Infant Mortality in the United States, 2005-2007. Pediatr Infect Dis J. 2012 Mar 9. [Medline].

  8. Vernacchio L, Vezina RM, Mitchell AA, Lesko SM, Plaut AG, Acheson DW. Diarrhea in American infants and young children in the community setting: incidence, clinical presentation and microbiology. Pediatr Infect Dis J. 2006 Jan. 25(1):2-7. [Medline].

  9. Guarino A, Albano F, Ashkenazi S, et al. European Society for Paediatric Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: executive summary. J Pediatr Gastroenterol Nutr. 2008 May. 46(5):619-21. [Medline].

  10. [Guideline] Atia AN, Buchman AL. Oral rehydration solutions in non-cholera diarrhea: a review. Am J Gastroenterol. 2009 Oct. 104(10):2596-604; quiz 2605. [Medline].

  11. Guandalini S. Probiotics for prevention and treatment of diarrhea. J Clin Gastroenterol. 2011 Nov. 45 Suppl:S149-53. [Medline].

  12. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006 Jan 5. 354(1):11-22. [Medline]. [Full Text].

  13. Soares-Weiser K, MacLehose H, Bergman H, Ben-Aharon I, Nagpal S, Goldberg E, et al. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database of Systematic Reviews. 2012.

  14. Platts-Mills JA, Babji S, Bodhidatta L, et al. Pathogen-specific burdens of community diarrhoea in developing countries: a multisite birth cohort study (MAL-ED). Lancet Glob Health. 2015 Sep. 3 (9):e564-75. [Medline].

  15. Abubakar I, Aliyu SH, Arumugam C, Usman NK, Hunter PR. Treatment of cryptosporidiosis in immunocompromised individuals: systematic review and meta-analysis. Br J Clin Pharmacol. 2007 Apr. 63(4):387-93. [Medline].

  16. Barclay L. Zinc supplements reduce diarrhea in children. Medscape Medical News. May 15, 2014. [Full Text].

  17. Bellemare S, Hartling L, Wiebe N, et al. Oral rehydration versus intravenous therapy for treating dehydration due to gastroenteritis in children: a meta-analysis of randomised controlled trials. BMC Med. 2004 Apr 15. 2:11. [Medline]. [Full Text].

  18. Bryce J, Boschi-Pinto C, Shibuya K, Black RE,. WHO estimates of the causes of death in children. Lancet. 2005 Mar 26-Apr 1. 365(9465):1147-52. [Medline].

  19. Charles MD, Holman RC, Curns AT, et al. Hospitalizations associated with rotavirus gastroenteritis in the United States, 1993-2002. Pediatr Infect Dis J. 2006 Jun. 25(6):489-93. [Medline].

  20. Coffin SE, Elser J, Marchant C, et al. Impact of acute rotavirus gastroenteritis on pediatric outpatient practices in the United States. Pediatr Infect Dis J. 2006 Jul. 25(7):584-9. [Medline].

  21. Girard MP, Steele D, Chaignat CL, Kieny MP. A review of vaccine research and development: human enteric infections. Vaccine. 2006 Apr 5. 24(15):2732-50. [Medline].

  22. Guandalini S. Treatment of acute diarrhea in the new millennium. J Pediatr Gastroenterol Nutr. 2000 May. 30(5):486-9. [Medline].

  23. Guandalini S, Dincer AP. Nutritional management in diarrhoeal disease. Baillieres Clin Gastroenterol. 1998 Dec. 12(4):697-717. [Medline].

  24. Guandalini S, Kahn S. Acute diarrhea. Walker A, Goulet O, Kleinman J, et al eds. Pediatric Gastrointestinal Disease. Ontario, Canada: Brian C. Decker; 2008. Vol 1: 252-64/Chapter 15.

  25. Matson DO, Staat MA, Azimi P, Itzler R, Bernstein DI, Ward RL, et al. Burden of rotavirus hospitalisations in young children in three paediatric hospitals in the United States determined by active surveillance compared to standard indirect methods. J Paediatr Child Health. 2012 Apr 25. [Medline].

  26. Mayo-Wilson E, Junior JA, Imdad A, Dean S, Chan XH, Chan ES, et al. Zinc supplementation for preventing mortality, morbidity, and growth failure in children aged 6 months to 12 years of age. Cochrane Database Syst Rev. 2014 May 15. 5:CD009384. [Medline].

  27. Miller RC, Petereit DG, Sloan JA, et al. A phase III randomized study of sulfasalazine versus placebo in the prevention of acute diarrhea in patients receiving pelvic radiation therapy [abstract LBA2]. Presented at American Society for Radiation Oncology (ASTRO) 55th Annual Meeting; September 22, 2013; Atlanta, Georgia.

  28. Mulcahy N. Recommended drug may cause diarrhea with radiation. October 3, 2013. Medscape Medical News. Available at Accessed: October 7, 2013.

  29. Sandhu BK, Isolauri E, Walker-Smith JA, et al. A multicentre study on behalf of the European Society of Paediatric Gastroenterology and Nutrition Working Group on Acute Diarrhoea. Early feeding in childhood gastroenteritis. J Pediatr Gastroenterol Nutr. 1997 May. 24(5):522-7. [Medline].

  30. Sullivan PB. Nutritional management of acute diarrhea. Nutrition. 1998 Oct. 14(10):758-62. [Medline].

  31. [Guideline] Walker-Smith JA, Sandhu BK, Isolauri E, et al. Guidelines prepared by the ESPGAN Working Group on Acute Diarrhoea. Recommendations for feeding in childhood gastroenteritis. European Society of Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr. 1997 May. 24(5):619-20. [Medline].

Table 1. Stool Characteristics and Determining Their Source
Stool Characteristics Small Bowel Large Bowel
Appearance Watery Mucoid and/or bloody
Volume Large Small
Frequency Increased Highly increased
Blood Possibly positive but never gross blood Commonly grossly bloody
pH Possibly < 5.5 >5.5
Reducing substances Possibly positive Negative
WBCs < 5/high power field Commonly >10/high power field
Serum WBCs Normal Possible leukocytosis, bandemia
Organisms Viral
  • Rotavirus
  • Adenovirus
  • Calicivirus
  • Astrovirus
  • Norovirus
Invasive bacteria
  • Escherichia Coli (enteroinvasive, enterohemorrhagic)
  • Shigella species
  • Salmonella species
  • Campylobacter species
  • Yersinia species
  • Aeromonas species
  • Plesiomonas species
Enterotoxigenic bacteria
  • E coli
  • Klebsiella
  • Clostridium perfringens
  • Cholera species
  • Vibrio species
Toxic bacteria
  • Clostridium difficile
  • Giardia species
  • Cryptosporidium species
  • Entamoeba organisms
Table 2. Organisms and Frequency of Symptoms
Organism Incubation Duration Vomiting Fever Abdominal Pain
Rotavirus 1-7 d 4-8 d Yes Low No
Adenovirus 8-10 d 5-12 d Delayed Low No
Norovirus 1-2 d 2 d Yes No No
Astrovirus 1-2 d 4-8 d +/- +/- No
Calicivirus 1-4 d 4-8 d Yes +/- No
Aeromonas species None 0-2 wk +/- +/- No
Campylobacter species 2-4 d 5-7 d No Yes Yes
C difficile Variable Variable No Few Few
C perfringens Minimal 1 d Mild No Yes
Enterohemorrhagic E coli 1-8 d 3-6 d No +/- Yes
Enterotoxigenic E coli 1-3 d 3-5 d Yes Low Yes
Plesiomonas species None 0-2 wk +/- +/- +/-
Salmonella species 0-3 d 2-7 d Yes Yes Yes
Shigella species 0-2 d 2-5 d No High Yes
Vibrio species 0-1 d 5-7 d Yes No Yes
Y enterocolitica None 1-46 d Yes Yes Yes
Giardia species 2 wk 1+ wk No No Yes
Cryptosporidium species 5-21 d Months No Low Yes
Entamoeba species 5-7 d 1-2+ wk No Yes No
Table 3. Dehydration Severity, Signs, and Symptoms
Hydration 0-5% Dehydration


5-10% Dehydration


10% or More


General Well Restless Lethargic
Eyes Normal Sunken Very sunken
Tears Present Absent Absent
Mouth Moist Dry Very dry
Thirst Drinks normally Thirsty Drinks poorly
Skin Pinch retracts immediately Pinch retracts slowly Pinch stays folded
Table 4. Common Bacteria and Optimum Culture Mediums
Organism Detection Method Microbiologic Characteristics
Aeromonas species Blood agar Oxidase-positive flagellated gram-negative bacillus (GNB)
Campylobacter species Skirrow agar Rapidly motile curved gram-negative rod (GNR); Campylobacter jejuni 90% and Campylobacter coli 5% of infections
C difficile Cycloserine-cefoxitin-fructose-egg (CCFE) agar; enzyme immunoassay (EIA) for toxin; latex agglutination (LA) for protein Anaerobic spore-forming gram-positive rod (GPR); toxin-mediated diarrhea; produces pseudomembranous colitis
C perfringens None available Anaerobic spore-forming GPR; toxin-mediated diarrhea
E coli MacConkey eosin-methylene blue (EMB) or Sorbitol-MacConkey (SM) agar Lactose-producing GNR
Plesiomonas species Blood agar Oxidase-positive GNR
Salmonella species Blood, MacConkey EMB, xylose-lysine-deoxycholate (XLD), or Hektoen enteric (HE) agar Nonlactose non–H2S-producing GNR
Table 5. Probiotic Efficacy in Diarrhea
Condition Patients and Controls Most-Studied Probiotics Evidence of Efficacy

(- to +++)

Prevention of Daycare Diarrhea 2000 Lactobacillus GG

Bifidobacterium lactis

Lactobacillus reuteri

Lactobacillus casei

Bifidobacterium bifidum + Streptococcus thermophilus

Prevention of Nosocomial Diarrhea 1000 Lactobacillus GG ++
Prevention of Antibiotic-Associated Diarrhea 2000 Lactobacillus GG

Saccharomyces boulardii

Infectious Diarrhea 3500 Lactobacillus GG

Saccharomyces boulardii

Persistent Diarrhea 460 Lactobacillus GG +
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.